Engflag

Imazol Paste

Quick links to important sections

Imazol Paste

Imazol Paste_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imazol Paste

Quick Facts

Property Description
Active ingredient Clotrimazole, Phenylethyl Alcohol
Form Dermatological Paste (Cremepaste)
Pharmacological class Antimycotic and Antiseptic
Common use Superficial fungal and yeast skin infections
Origin Synthetic (Clotrimazole)

What is Imazol Paste? Identity, Class, and Formulation

Imazol Paste is defined as a synthetic combination medicinal preparation specifically formulated for topical (dermatological) application. Its identity is centered on the principal active ingredient, Clotrimazole, which is clinically recognized as a core substance within the Azole antifungal class, widely utilized for its broad spectrum of activity against various pathogenic fungi. The product is classified as a combination agent because it integrates two active components within a highly adherent paste base, distinguishing it from conventional, less localized cream formulations.

The Dual Composition: Clotrimazole and Phenylethyl Alcohol

The preparation’s efficacy results from the integration of the primary therapeutic agent, Clotrimazole, and the functional additive, Phenylethyl Alcohol. Clotrimazole performs the core antifungal action, while Phenylethyl Alcohol functions as a mild antimicrobial preservative and secondary antiseptic, offering localized protective properties. This combination product utilizes a specialized lipophilic paste base, which is distinctively designed for high adherence and a localized protective action, offering particular utility in scenarios where managing excessive moisture is necessary, such as certain cases of diaper dermatitis.

General Purpose and Foundational Mechanism

The general purpose of Imazol Paste is to provide relief and support skin recovery by simultaneously targeting fungal organisms and managing the affected skin environment. The foundational mechanism involves Clotrimazole interfering with the structural integrity of the fungal cell membrane, thereby halting the organism’s ability to thrive and spread. The paste formulation further contributes to its efficacy by providing a protective, moisture-absorbing barrier, which is essential for managing the often wet and macerated skin areas associated with these superficial infections.

Regulatory References

  1. FDA DailyMed: Clotrimazole Cream Label

What side effects are possible with Imazol Paste?

Possible side effects and safety information

The officially documented safety profile for Imazol Paste, which contains the active ingredient Clotrimazole, is largely characterized by localized reactions at the application site. Regulatory documents classify potential adverse reactions based on frequency and affected body systems.

Adverse Reaction Scope

The most frequently reported side effects are localized, falling under Skin and Subcutaneous Tissue Disorders. These are often categorized as Common and may include local irritation, a stinging or burning sensation, erythema (redness), and pain at the site of application.

Severe, yet rare, adverse reactions are also officially documented within the Immune System Disorders category. These include generalized hypersensitivity reactions, angioedema, and anaphylactic reactions. These serious events are listed as having an Uncertain Frequency, typically based on post-marketing surveillance.

Safety Considerations and Limitations

For specific populations, the safety profile relies on the established minimal systemic absorption of the active ingredient after topical application. This characteristic makes harmful systemic effects unlikely during use in pregnancy or lactation. The formulation's safety structure also requires caution in individuals with known hypersensitivity to Clotrimazole or any excipient. Furthermore, regulatory documents note that Clotrimazole may potentially damage certain latex contraceptive devices (such as condoms or diaphragms), which should be considered a functional safety restriction of the active substance.

Overdose and Emergency Response

Overdose and when to seek help

Imazol Paste contains clotrimazole, a topical antifungal agent. The official information regarding overdose is primarily focused on accidental ingestion of the product, as systemic absorption through the skin is considered minimal following correct topical use.

Overdose Scenario
Accidental Ingestion (Swallowing) The product is not intended for oral use and may cause harm if swallowed. Official guidance states to contact a doctor or poison control center immediately if the medication is ingested.
Severe Allergic Reaction While rare, a serious allergic reaction (anaphylaxis) requires immediate emergency medical attention. Symptoms may include sudden swelling of the lips, mouth, or throat, or difficulty breathing, fainting, or unconsciousness.

Emergency Response Statements (Official Phrasing):

  • If someone swallows clotrimazole topical, call a doctor or local poison control center right away (for US-based labels, 1-800-222-1222 is often cited).
  • If the person has collapsed or is not breathing, call local emergency services (911 in the US).
  • Do not try to make the person vomit unless instructed to do so by medical personnel.

Overdose Context: The risk of systemic overdose is constrained to the circumstance of oral exposure to large quantities of the paste, rather than excessive topical application. The drug's safety profile notes that only negligible amounts are typically absorbed through intact skin, making dermal application highly unlikely to result in an overdose requiring systemic intervention.

Therapeutic Uses of Imazol Paste

What Imazol Paste Treats: Main Uses and Benefits

This preparation is commonly used in situations involving certain distressing symptoms related to superficial mycotic diseases, including various Tinea infections, Intertrigo (rash in skin folds), and skin Candidiasis (yeast infections). It is relevant for addressing a range of dermatomycoses, particularly in contexts marked by increased discomfort.

The medication is applied to ease symptom clusters that may interfere with daily functioning, such as intense itching (pruritus), a burning sensation, and pronounced inflammatory redness. It may assist with moderating the intensity of these symptoms, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations. The formulation is particularly relevant for infections in moisture-prone areas like skin folds, where the paste formulation is relevant for managing conditions complicated by excessive moisture.

In the pediatric population, it is generally used to address diaper dermatitis when the rash is complicated by a secondary yeast infection. This application provides support that may contribute to easing the discomfort associated with the inflammation.

“The paste formulation is considered relevant in clinical settings where managing wet, macerated skin is important for symptomatic assistance.”

Quick Fact: Relief for Pruritus and Inflammation

Imazol Paste supports the management of acute or disruptive episodes associated with fungal proliferation, contributes to easing discomfort and supports general well-being by easing inflammatory and irritative states.

Regulatory References

  1. authoritative review on Clotrimazole indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Imazol Paste?

Eligibility for Imazol Paste is determined by regulatory bodies based on population type and specific medical history, reflecting the product's composition (Clotrimazole and Phenylethyl Alcohol) and topical application.

Populations for Whom Use is Prohibited or Restricted

Category Official Regulatory Statement
Absolute Contraindication Use is contraindicated in patients with known hypersensitivity to the active substances (Clotrimazole, Phenylethyl Alcohol) or any excipients in the paste formulation.
Pregnancy Eligibility Use is permitted if deemed essential but must be restricted and should not be applied over extensive skin areas.
Lactation Eligibility Use is restricted; the paste must not be applied to the area of the breasts to prevent potential ingestion by the infant.

Populations with Established Use

Imazol Paste is generally permitted for use in adults for labeled indications. Use is also established in the pediatric population, specifically infants and children, for conditions such as candidal diaper dermatitis. Official labeling does not contain restrictions based on the patient's hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Imazol Paste (topical Clotrimazole) around its route of administration and corresponding minimal systemic risk. Due to the negligible absorption of Clotrimazole into the bloodstream when applied to the skin, a risk of systemic drug-drug interactions is not formally documented in regulatory prescribing information.

Minimal Systemic Interaction Profile

No systemic medicinal products are formally listed as contraindicated for co-administration with this topical paste, and there are no mandatory timing-separation requirements specified in official labeling. Because systemic exposure is minimal, the risk of altered plasma concentrations or reduced clearance of co-administered medicines, such as those related to Cytochrome P450 (CYP) enzyme metabolism, is not a documented interaction concern.

Local Pharmacodynamic Interactions

Regulatory documents address potential interactions with other antifungal agents applied locally. The official prescribing information states that no synergism or antagonism has been reported when Clotrimazole is tested alongside other agents like Nystatin, Amphotericin B, or Flucytosine against Candida albicans strains. This establishes the documented pattern for co-application of different antifungal compounds at the treatment site. No interactions with food, alcohol, or supplements are documented for this topical formulation.

Mechanism of Action

The mechanism of Imazol Paste combines two distinct, localized actions: metabolic inhibition and physical cell membrane disruption.

The primary action, driven by Clotrimazole, targets the essential fungal enzyme lanosterol 14-alpha-demethylase. By inhibiting this enzyme, the drug blocks the biosynthesis pathway for ergosterol, the primary sterol for fungal cell membranes. This mechanism causes the accumulation of toxic sterols and compromises the structural and functional integrity of the fungal cell membrane, resulting in fungal cell death.

The secondary component, Phenylethyl Alcohol, exerts a different, physical disruption mechanism by inserting itself directly into the lipid bilayer of microbial cell membranes. This process rapidly destabilizes the membrane, increasing its permeability and causing the unregulated leakage of vital intracellular components. This non-specific action contributes an antiseptic action and enhances the breakdown of the microbial barrier.

Dosage and Administration Information

Official Administration Principles

The use of Imazol Paste, a dermatological preparation containing 1% Clotrimazole, is governed by specific administration protocols. The medicine is designed exclusively for topical application and must not be used on mucosal surfaces or ingested.

The primary method of use involves applying a thin layer of the paste, ensuring coverage extends beyond the visible affected area to the immediate surrounding skin. The official frequency standard requires application twice daily, typically scheduled for the morning and evening, to maintain consistent exposure to the active substance.

Treatment Duration and Procedural Conditions

The total duration of use is standardized and depends on the specific condition being managed. Prescribing information establishes a fixed course of two weeks for certain indications, and up to four weeks for others, such as Tinea Pedis. Administration is mandated to continue for the full duration regardless of the immediate improvement of symptoms.

Before each application, the affected area must be thoroughly cleaned and dried to fulfill the requirements for proper use. The paste formulation is not effective for infections located on the scalp or nails, and contact with the eyes must be strictly avoided as a procedural constraint. Furthermore, general use is not recommended for pediatric patients under 2 years of age unless specifically authorized by a physician.

Summary of Official Protocol

Parameter Official Specification
Route Topical (Dermal, External Use Only)
Frequency Twice Daily
Duration Fixed course of 2 to 4 weeks
Preparation Area must be clean and dry

Recent Clinical Evidence

Research evidence / Overview of studies for Imazol Paste

Evidence for use in Diaper Dermatitis (Yeast Complication)

Research has examined the core antifungal component, Clotrimazole, in short-term Randomized Controlled Trials (RCTs) involving infants and children with secondary fungal infection. These studies monitored populations and explored changes over defined time intervals, usually seven to fourteen days, focusing on outcomes related to physical discomfort. Key metrics examined included the rate at which physical signs resolved and whether the fungus was eliminated (mycological clearance).

Findings describe patterns where the antifungal component was associated with measured changes in symptom scores and fungal levels within the short study period. However, comparative evidence is lacking for the unique combination paste versus an identical single-agent paste, and long-term effects regarding symptom patterns after treatment ends are not fully established.

Evidence for use in Superficial Skin Candidiasis and Tinea Infections

The evidence for the core antifungal agent in research exploring infections like Tinea (ringworm, athlete’s foot) and general Cutaneous Candidiasis is derived from Controlled Clinical Trials and high-level Systematic Reviews of the azole class. These studies explored changes in the monitoring of objective physical signs and outcomes describing perceived discomfort, such as itching or burning.

The research describes patterns where the active ingredient was observed in some studies to have changes in physical signs and fungal clearance. The evidence quality varies across studies, as some data is synthesized from trials involving the broader class of antifungals, and the results apply only to the specific populations studied.

Research Gaps and Follow-up Duration

Most available research was studied for short-term scenarios, typically one to four weeks. Follow-up durations were limited to capture the immediate response, meaning long-term outcomes are not well characterized. Evidence for specific groups, such as the older adult population or patients with other existing medical conditions, is often not distinctly detailed.

A key area of uncertainty is the specific role of the combination of Clotrimazole and Phenylethyl Alcohol in the high-adherence paste base, as comparative evidence is lacking to definitively isolate its contribution.

Key Studies & References Clotrimazole: Indications and Therapeutic Use (StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Imazol Paste (FAQ)

Q: Is Imazol Paste meant to treat fungal infections, bacterial infections, or both?

According to official regulatory information, Imazol Paste primarily targets fungal infections due to its main active ingredient, the antifungal Clotrimazole. The formulation also contains Phenylethyl Alcohol, which is described as a mild antimicrobial preservative that provides a secondary antiseptic action.

Q: How is Imazol Paste different from a standard antifungal cream?

Official descriptions indicate that Imazol Paste differs from standard antifungal creams due to its specialized lipophilic paste base. This paste is specifically designed for high adherence to the skin and provides a localized protective, moisture-absorbing barrier.

Q: Can the paste be applied to broken or irritated skin?

Official procedural conditions describe the affected skin area should be thoroughly cleaned and dried before each application. Regulatory documents often restrict the use of topical products on actively broken skin to prevent increased systemic absorption, indicating that application to broken skin is a high-risk scenario for topical absorption.

Q: Does the paste formulation help the active ingredient stay on the skin longer?

Official formulation descriptions confirm the paste is designed for high adherence. This characteristic helps the active ingredients to remain localized. The paste provides a protective action for managing skin areas prone to excessive moisture.

Q: Can I use moisturizers or other products on the skin while using Imazol Paste?

Official documents explicitly state that no interactions with food, alcohol, or supplements are documented for this topical product. However, there is no specific regulatory mention of topical moisturizers or cosmetics. The general official administration protocol specifies that the affected area must be clean and dry before the paste is applied.

Q: Does Imazol Paste carry a risk of the infection returning once treatment is stopped?

Studies and official research reviews indicate that most trials examining the drug were short-term, typically lasting one to four weeks. Due to the limited duration of follow-up in the available evidence, long-term outcomes regarding the recurrence of symptoms after treatment ends are not well characterized.

Q: Are there any official statements about Imazol Paste's use in elderly patients?

The official research summary notes a gap in the available data for certain populations. It states that evidence specifically detailing the use or effects of the drug in the older adult population is often not distinctly detailed in the studies reviewed.

Q: How long does it usually take to see a noticeable effect from Imazol Paste?

Regulatory guidance establishes a timeframe for monitoring improvement by stating that medical review is advised if the condition has not improved after 7 days (or after 3 days for candidal diaper rash). This guidance is used to establish an expected timeframe for initial effect.

Q: Does Imazol Paste contain any steroids?

The official composition lists the active ingredients as the antifungal Clotrimazole and the antiseptic Phenylethyl Alcohol. Regulatory documents describing this specific Imazol Paste formulation do not declare the presence of any corticosteroid (steroid) component.

Q: Is Imazol Paste typically available over-the-counter or by prescription only?

According to official regulatory status in many regions, the medicine is classified as non-prescription (over-the-counter). However, it often remains subject to dispensing regulations that may require it to be obtained directly from a pharmacy.

Q: Does Imazol Paste cause the treated skin area to be sensitive to sunlight?

Official regulatory documents containing side effect profiles for topical Clotrimazole do not commonly list photosensitivity (increased skin sensitivity when exposed to sunlight) as a potential adverse reaction.

Q: What should be done if the side effects of Imazol Paste seem to be worsening?

Official guidance states that if symptoms worsen or do not show improvement within the expected treatment period, seeking advice from a health professional is generally appropriate.

Q: What are the main inactive ingredients in Imazol Paste?

The regulatory composition lists several non-active components, or excipients. These include substances such as Butylhydroxyanisole (E320), Cetylstearyl alcohol, Titanium dioxide (E171), and liquid paraffin, among others.

Q: Are there different strengths or formulations of Imazol Paste available?

While the core product is defined as a 1% Clotrimazole paste, official product listings indicate that other formulations or combination products containing Clotrimazole under the Imazol brand may be available, depending on the country or region.

Q: What is the difference between Imazol Paste and similar-sounding products with a different active ingredient?

Regulatory documents define Imazol Paste by its two declared active ingredients, Clotrimazole and Phenylethyl Alcohol, and its official therapeutic purpose. Official information does not provide comparative claims against other antifungal products that contain different active ingredients.

Q: Where can I find the official patient information leaflet for Imazol Paste online?

Official patient information leaflets (PILs) and the Summary of Product Characteristics (SmPCs) are publicly accessible regulatory documents. These can typically be found on the websites of the national drug regulatory authorities (such as the FDA, EMA, or MHRA) where the product is approved.

Q: What are the typical signs of improvement to look for when using Imazol Paste?

Research studies monitor changes in symptom scores and physical signs, along with the rate of fungal elimination. Official guidance states that treatment should continue for the full duration even after inflammation and other symptoms have subsided.

Q: What should be done if an application of Imazol Paste is missed?

Standard protocol for a twice-daily topical application suggests the missed dose may be applied as soon as it is remembered. However, if the timing is close to the next scheduled dose, the missed dose is generally skipped, and the patient resumes the regular dosing schedule.

How should Imazol Paste be stored and disposed of?

How to Store and Dispose of Imazol Paste?

Imazol Paste must be stored according to official regulatory conditions to maintain its stability and effectiveness. The product requires storage at a controlled room temperature, typically between 20^circ to 25 C (68^circ to 77 F), and must be kept from freezing.

Official Storage and Handling

Requirement Description
Temperature & Environment Store away from direct light, excess heat, and moisture.
Container Integrity Keep the container tightly closed and in its original tube. Do not use if the safety seal is broken.
Child Safety Keep out of the sight and reach of children. Seek medical help immediately if swallowed.
Disposal Do not dispose of unused or expired medicine in household waste or wastewater. Return the product to a pharmacy or designated medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Imazol Paste found in:

A-Z Index: